Terg R, Llano K, Cobas S M, Brotto C, Barrios A, Levi D, Wasen W, Bartellini M A
Unidad de Hepatología, Hospital Municipal de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina.
J Hepatol. 1998 Sep;29(3):437-42. doi: 10.1016/s0168-8278(98)80062-7.
BACKGROUND/AIMS: Selective intestinal decontamination has been proposed to prevent spontaneous bacterial peritonitis in cirrhosis. Because of the cost of antibiotics and the development of resistant bacteria, we have evaluated the effect of different schemes and doses of oral ciprofloxacin on aerobic gram-negative fecal flora in cirrhotic patients.
Twenty-nine cirrhotic patients were allocated to four groups to receive: Group 1: 500 mg/day for 2 weeks (six patients); Group 2: 1000 mg twice a week for 2 weeks (six patients); Group 3: 1000 mg once a week for 2 weeks (six patients); and Group 4: 1000 mg once a week for 12 weeks (11 patients). Quantitative analysis of the gram-negative fecal flora was performed before and 1 and 2 weeks after initiation of treatment in patients in Groups 1, 2 and 3 and before and 4, 8 and 12 weeks after initiation of treatment in patients in Group 4.
Complete eradication of gram-negative bacilli was observed in four of six patients in Group 1. In contrast, only one patient eradicated gram-negative bacilli in Group 2 and Group 3. In long-term administration of ciprofloxacin (Group 4), only two of 11 patients had persistent eradication of gram-negative bacilli. Four patients developed E. coli resistant to ciprofloxacin (one of them associated to resistant Klebsiella). No patient developed bacterial infection during the study period.
Oral ciprofloxacin administered in a weekly dose is ineffective in selective intestinal decontamination. Different mechanisms, including the emergence of ciprofloxacin-resistant organisms, could account for this failure. Therefore, our results suggest that weekly administration of ciprofloxacin is not useful in preventing spontaneous bacterial peritonitis.
背景/目的:有人提出采用选择性肠道去污法预防肝硬化患者发生自发性细菌性腹膜炎。鉴于抗生素的成本及耐药菌的产生,我们评估了不同方案及剂量的口服环丙沙星对肝硬化患者需氧革兰氏阴性粪便菌群的影响。
29例肝硬化患者被分为四组,分别接受以下治疗:第1组:每日500毫克,共2周(6例患者);第2组:每周2次,每次1000毫克,共2周(6例患者);第3组:每周1次,每次1000毫克,共2周(6例患者);第4组:每周1次,每次1000毫克,共12周(11例患者)。对第1、2和3组患者在治疗开始前、治疗开始后1周和2周进行革兰氏阴性粪便菌群定量分析,对第4组患者在治疗开始前、治疗开始后4周、8周和12周进行革兰氏阴性粪便菌群定量分析。
第1组6例患者中有4例革兰氏阴性杆菌被完全清除。相比之下,第2组和第3组仅各有1例患者革兰氏阴性杆菌被清除。在长期服用环丙沙星的患者(第4组)中,11例患者中只有2例革兰氏阴性杆菌持续被清除。4例患者出现对环丙沙星耐药的大肠杆菌(其中1例与耐药克雷伯菌有关)。在研究期间无患者发生细菌感染。
每周给药一次的口服环丙沙星在选择性肠道去污方面无效。包括环丙沙星耐药菌出现在内的不同机制可能导致了这种失败。因此,我们的结果表明,每周服用环丙沙星对预防自发性细菌性腹膜炎无用。